![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Treatment of decompensated HCV cirrhosis in patients with diverse genotypes:
12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV Genotypes 1 and 3
|
|
|
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
GR Foster, J. McLauchlan, W. Irving,
M. Cheung, B. Hudson, S. Verma, K. Agarwal, HCV Research UK EAP Group
![EASL1.gif](../images/042415/042415-13/EASL1.gif)
![EASL2.gif](../images/042415/042415-13/EASL2.gif)
![EASL3.gif](../images/042415/042415-13/EASL3.gif)
![EASL4.gif](../images/042415/042415-13/EASL4.gif)
![EASL5.gif](../images/042415/042415-13/EASL5.gif)
![EASL6.gif](../images/042415/042415-13/EASL6.gif)
![EASL7.gif](../images/042415/042415-13/EASL7.gif)
![EASL8.gif](../images/042415/042415-13/EASL8.gif)
![EASL9.gif](../images/042415/042415-13/EASL9.gif)
![EASL10.gif](../images/042415/042415-13/EASL10.gif)
![EASL11.gif](../images/042415/042415-13/EASL11.gif)
![EASL12.gif](../images/042415/042415-13/EASL12.gif)
![EASL13.gif](../images/042415/042415-13/EASL13.gif)
![EASL14.gif](../images/042415/042415-13/EASL14.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|